Tesamorelin (Pen)

Tesamorelin (Pen) is the pre-filled pen version of Revitalized Research’s tesamorelin listing, available in 10 mg and 30 mg fills. Inside is the same research compound as the vial: tesamorelin (TH9507), a 44-residue synthetic analog of human growth hormone-releasing hormone with an N-terminal trans-3-hexenoyl modification.^{17214611, 19243281} This page covers what the pen format changes for a laboratory: fill strength, labelling, storage and documentation. A batch certificate card is posted on this page. Supplied for qualified laboratory research only.

Compound identity

Research literature

Tesamorelin (TH9507) is a synthetic 44-residue analog of GHRH(1-44) carrying a trans-3-hexenoyl group at the N-terminus, studied as a ligand of the GHRH receptor. This listing is the pre-filled pen format. Primary sources are linked below for researchers who need the original papers. This listing does not summarise study outcomes and makes no claim about any effect, use or benefit of this product, which is supplied as a reference material for in vitro laboratory research only.

References (PubMed): PMID 17214611, PMID 19243281, PMID 15113616, PMID 25358450, PMID 25895899, PMID 18057338, PMID 20101189

Batch documentation

The certificate card on this listing is titled “Tesamorelin 10mg (Pen)”. It shows batch RRL-1700427-P, purity 99.39%, dated 27 JUN 2026, from horizonanalytical.com. The report images behind the card describe a UPLC-MS analysis of a 10 mg specification. The 30 mg fill does not have its own certificate on the page at the moment; ask support for 30 mg lot paperwork before you rely on it.

Check the lot on the pen label against the card, then confirm the report with the testing lab. Posted certificates for the whole range sit in the COA library, and the step-by-step guide on verifying a peptide COA covers lab look-ups and red flags.

Storage and handling

The vial and the pen differ most in handling. A vial ships as dry powder, and the lab reconstitutes it on its own schedule. A pen arrives as a prepared format, so temperature control starts the moment it arrives. Log the receipt date, refrigerate the pen, keep it out of light and away from freezer walls, and keep each pen in its own labelled slot so the 10 mg and 30 mg fills cannot be confused. Labs that prefer to prepare their own solutions can use the vial listing with reconstitution solution, which is sold separately. For general practice, see peptide storage basics for research labs.

Frequently asked questions

Is the pen the same compound as the Tesamorelin vial?

Yes. Both listings concern tesamorelin (TH9507), the trans-3-hexenoyl-modified GHRH(1-44) amide analog indexed in PubChem as CID 16137828. The pen is a different presentation of that compound, not a different peptide.

What do the 10 mg and 30 mg options mean?

They are the two fill strengths offered on this listing: the total tesamorelin content stated for one pen. Choose the option your protocol calls for and confirm the strength on the pen label when it arrives.

Which certificate covers this pen listing?

The certificate card on this page is titled Tesamorelin 10mg (Pen) and shows batch RRL-1700427-P, purity 99.39%, dated 27 JUN 2026, from horizonanalytical.com. The report tests a 10 mg quantity. No separate certificate for the 30 mg fill is shown on the page at present, so contact support for 30 mg lot documentation.

How should a tesamorelin pen be stored?

Keep pens refrigerated, protected from light and upright in a labelled rack. Avoid freezing and repeated temperature cycling, and follow the label and your institution’s SOPs. A solution-format peptide calls for closer temperature control than a sealed lyophilized vial.

For research use only. Not for human or animal consumption, administration, injection, topical use, medical, clinical, veterinary, food, cosmetic, supplement, household, or other personal use. This site does not provide medical advice, and this product is not intended to diagnose, treat, cure, mitigate, or prevent any disease.

These statements have not been evaluated by the Food and Drug Administration. Review the available COA or batch documentation and follow applicable laws, institutional protocols, and safety procedures before handling.

COA documentation is organized by product and batch whenever available.

Store and handle according to the product label, batch documentation, and laboratory protocol.